G100

Generic Name: G100

Drug Type: Biotech

Clinical Trials

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of the Sm-p80 + GLA-SE (SchistoShield®) Candidate Vaccine in Healthy Adults in Burkina Faso and Madagascar

Phase 1

Active, not recruiting

Conditions: Schistosomiasis

Interventions: Biological: Sm-p80 + GLA-SE

First Posted Date: 2023-03-09

Last Posted Date: 2025-04-02

Lead Sponsor: International Vaccine Institute

Target Recruit Count: 120

Registration Number: NCT05762393

Locations: 🇧🇫
Groupe de Recherche Action en Santé (GRAS), Ouagadougou, Burkina Faso
🇲🇬
Madagascar Institute for Vaccine Research (University of Antananarivo), Antananarivo, Madagascar

Safety, Tolerability, and Immunogenicity Study of Sm-p80 + GLA-SE (SchistoShield(R)) Vaccine in Healthy Adults

Phase 1

Completed

Conditions: Schistosomiasis

Interventions: Biological: Sm-p80 + GLA-SE
Biological: Sm-p80

First Posted Date: 2022-03-23

Last Posted Date: 2025-04-11

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 45

Registration Number: NCT05292391

Locations: 🇺🇸
Kaiser Permanente Washington Health Research Institute, Seattle, Washington, United States

Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of HIV-1 Chimp Adenovirus Vaccines Expressing Clade C gp140 & CH505TF gp120 Protein Boost in HIV-uninfected Adult.

Phase 1

Active, not recruiting

Conditions: HIV Infections

Interventions: Biological: AdC6-HIVgp140
Biological: Placebo
Biological: AdC7-HIVgp140
Biological: CH505TF gp120
Biological: GLA-SE (glucopyranosyl lipid A - stable emulsion; [labeled as AP 10-201])

First Posted Date: 2022-01-10

Last Posted Date: 2024-11-27

Lead Sponsor: HIV Vaccine Trials Network

Target Recruit Count: 34

Registration Number: NCT05182125

Locations: 🇿🇦
CAPRISA eThekwini CRS, Durban, South Africa
🇿🇦
Emavundleni CRS, Cape Town, South Africa
🇿🇦
Setshaba Research Centre CRS, Soshanguve, South Africa

and more 3 locations

Study of Intratumoral Ipilimumab and TLR4 Agonist GLA-SE in Combination With Systemic Nivolumab and Chemotherapy

Phase 1

Withdrawn

Conditions: Colorectal Cancer Metastatic

Interventions: Drug: FOLFOX regimen
Drug: Nivolumab
Drug: GLA-SE
Drug: Ipilimumab

First Posted Date: 2019-06-11

Last Posted Date: 2020-02-17

Lead Sponsor: Gustave Roussy, Cancer Campus, Grand Paris

Registration Number: NCT03982121

Locations: 🇫🇷
Gustave Roussy, Villejuif, Val De Marne, France

Anti-Schistosomiasis Vaccine: Sm14 Phase 2b-Sn in School Children

Phase 2

Completed

Conditions: Schistosomiasis

Interventions: Biological: Sm14
Drug: GLA-SE solution

First Posted Date: 2019-01-10

Last Posted Date: 2019-12-09

Lead Sponsor: Oswaldo Cruz Foundation

Target Recruit Count: 95

Registration Number: NCT03799510

Locations: 🇸🇳
Biomedical Research Center EPLS, Saint Louis, Senegal

Study of Safety and Immune Response of the Sm14 Vaccine in Adults of Endemic Regions

Phase 2

Completed

Conditions: Schistosomiasis

Interventions: Biological: Sm14
Drug: GLA-SE solution

First Posted Date: 2017-02-03

Last Posted Date: 2017-12-14

Lead Sponsor: Oswaldo Cruz Foundation

Target Recruit Count: 30

Registration Number: NCT03041766

Locations: 🇸🇳
Biomedical Research Center EPLS, Saint Louis, Senegal

Trial to Evaluate the Safety and Immunogenicity of a Placental Malaria Vaccine Candidate (PRIMVAC ) in Healthy Adults

Phase 1

Completed

Conditions: Malaria

Interventions: Biological: PRIMVAC
Biological: Placebo
Biological: GLA-SE
Biological: Alhydrogel

First Posted Date: 2016-01-18

Last Posted Date: 2025-02-28

Lead Sponsor: Institut National de la Santé Et de la Recherche Médicale, France

Target Recruit Count: 68

Registration Number: NCT02658253

Locations: 🇧🇫
CNRFP, Ouagadougou, Burkina Faso
🇫🇷
CIC 1417, Paris, France

Study of Intratumoral G100 With Or Without Pembrolizumab or Rituximab In Participants With Follicular Non-Hodgkin's Lymphoma (MK-3475-174/IMDZ-G142)

Phase 1

Terminated

Conditions: Follicular Low Grade Non-Hodgkin's Lymphoma

Interventions: Drug: G100
Drug: Pembrolizumab
Drug: Rituximab

First Posted Date: 2015-07-17

Last Posted Date: 2020-09-09

Lead Sponsor: Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Target Recruit Count: 52

Registration Number: NCT02501473

MART-1 Antigen With or Without TLR4 Agonist GLA-SE in Treating Patients With Stage II-IV Melanoma That Has Been Removed by Surgery

Early Phase 1

Completed

Conditions: Stage IIIB Skin Melanoma
Stage IIA Skin Melanoma
Stage IIC Skin Melanoma
Stage IIIA Skin Melanoma
Stage IIIC Skin Melanoma
Stage IV Skin Melanoma
Stage IIB Skin Melanoma

Interventions: Biological: MART-1 Antigen
Other: Laboratory Biomarker Analysis
Drug: TLR4 Agonist GLA-SE

First Posted Date: 2014-12-19

Last Posted Date: 2020-01-14

Lead Sponsor: Mayo Clinic

Target Recruit Count: 23

Registration Number: NCT02320305

Locations: 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States

TLR4 Agonist GLA-SE and Radiation Therapy in Treating Patients With Soft Tissue Sarcoma That Is Metastatic or Cannot Be Removed by Surgery

Phase 1

Completed

Conditions: Stage III Adult Soft Tissue Sarcoma
Stage IV Adult Soft Tissue Sarcoma

Interventions: Other: Laboratory Biomarker Analysis
Radiation: Radiation Therapy
Drug: TLR4 Agonist GLA-SE

First Posted Date: 2014-07-03

Last Posted Date: 2019-11-06

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 16

Registration Number: NCT02180698

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy